SINGAPORE, Nov. 20, 2025 /PRNewswire/ — SUNMI, a global leader in smart commercial devices, has seen rapid international adoption of its CPad series since its launch later this year. The business tablet lineup, including the payment-integrated SUNMI CPad PAY, is replacing traditional multi-device setups across retail, food service, and finance sectors worldwide.
Solving Real Business Challenges
“Commercial spaces need integrated solutions, not fragmented gadgets,” said Jack Lin, Founder and CEO of SUNMI. “The CPad series was designed from the ground up to address the limitations of consumer tablets in business environments. Market response confirms we’re on the right track.”
Three Key Differentiators
Global Implementation Success
Future Development
With the CPad series establishing a new standard for business tablets, SUNMI continues to expand its commercial device ecosystem. The company’s commitment includes three-year warranty coverage and five-year product availability, ensuring long-term reliability for business partners.
The successful rollout demonstrates growing market preference for purpose-built commercial solutions over adapted consumer technology, positioning SUNMI for continued innovation in the smart business device space.
Logo – https://mma.prnewswire.com/media/2081156/5634918/sunmi_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/sunmi-cpad-series-gains-global-traction-with-all-in-one-design-302621686.html
HYDERABAD, India, July 1, 2026 /PRNewswire/ -- ICFAI Business School (IBS) opened the registration process for…
COLOMBO, Sri Lanka, July 1, 2026 /PRNewswire/ -- FitsAir, Sri Lanka's privately owned international airline,…
VICTORIA, Seychelles, June 30, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading,…
The new CFD instruments give traders early exposure to two of the world's most prominent…
BENGALURU, India, June 30, 2026 /PRNewswire/ -- Apollo Hospitals, Bangalore has become the first hospital in…
Scientists can now design potent antibiotics and rapidly prioritise vaccine targets through Claude Science, thanks…